D L Carlson Investment Group Inc. Sells 303 Shares of Repligen Co. (NASDAQ:RGEN)

D L Carlson Investment Group Inc. decreased its stake in shares of Repligen Co. (NASDAQ:RGEN) by 5.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,787 shares of the biotechnology company’s stock after selling 303 shares during the period. D L Carlson Investment Group Inc.’s holdings in Repligen were worth $833,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. grew its holdings in shares of Repligen by 1.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 363,379 shares of the biotechnology company’s stock worth $54,078,000 after acquiring an additional 5,478 shares during the period. Cerity Partners LLC boosted its holdings in shares of Repligen by 90.0% during the 3rd quarter. Cerity Partners LLC now owns 5,541 shares of the biotechnology company’s stock valued at $825,000 after buying an additional 2,625 shares in the last quarter. Bank of Montreal Can lifted its position in Repligen by 34.9% during the 3rd quarter. Bank of Montreal Can now owns 49,568 shares of the biotechnology company’s stock valued at $7,233,000 after acquiring an additional 12,816 shares during the period. Townsquare Capital LLC boosted its stake in Repligen by 5.0% during the third quarter. Townsquare Capital LLC now owns 14,106 shares of the biotechnology company’s stock worth $2,099,000 after acquiring an additional 670 shares in the last quarter. Finally, Glenmede Trust Co. NA lifted its holdings in shares of Repligen by 13.4% during the third quarter. Glenmede Trust Co. NA now owns 6,158 shares of the biotechnology company’s stock valued at $916,000 after purchasing an additional 728 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Trading Down 2.7 %

Shares of Repligen stock opened at $133.41 on Monday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a market capitalization of $7.49 billion, a PE ratio of -261.59, a P/E/G ratio of 4.54 and a beta of 0.95. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $184.98. The company’s fifty day simple moving average is $154.21 and its 200-day simple moving average is $148.19.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. As a group, equities analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on RGEN shares. Royal Bank of Canada increased their target price on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. HC Wainwright restated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. TD Cowen began coverage on shares of Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Finally, Evercore ISI began coverage on Repligen in a report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $178.64.

Insiders Place Their Bets

In other news, Director Margaret Pax acquired 250 shares of Repligen stock in a transaction dated Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.